Showing 3251-3260 of 3314 results for "".
- Some Companies Cancel, Reduce Planned Price Hikes Amid Continued Pressure Over US Drug Costs: Reporthttps://modernod.com/news/some-companies-cancel-reduce-planned-price-hikes-amid-continued-pressure-over-us-drug-costs-report/2480031/Novartis, Gilead Sciences, Roche, and Novo Nordisk have advised California health plans in recent weeks that the companies are rescinding or reducing previously announced price increases on at least 10 drugs, Bloomberg reported Tuesday. The moves come after California introduced legislation earli
- Ocular Therapeutix Announces NDA Resubmission of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-nda-resubmission-of-dextenza/2480054/Ocular Therapeutix has announced the resubmission of the company’s new drug application (NDA) to the FDA for its lead product candidate Dextenza (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmission is intended to address manufacturing defic
- Staar Surgical and Kobe Kanagawa Eye Clinic in Japan Announce Strategic Cooperation Agreementhttps://modernod.com/news/staar-surgical-and-kobe-kanagawa-eye-clinic-in-japan-announce-strategic-cooperation-agreement/2480068/Staar Surgical and Kobe Kanagawa Eye Clinic, with locations in Tokyo and Osaka, announced they have entered into a multi-year Strategic Cooperation Agreement to provide Staar’s EVO Visian ICL lenses as a primary and premium option for patients seeking visual freedom from spectacles and cont
- Alcon to Showcase New Products, Commitment to ECP Education at 2018 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-new-products-commitment-to-ecp-education-at-2018-optometrys-meeting/2480083/Alcon will introduce new products and educational resources to eye care professional (ECP) and paraoptometric audiences at this year’s American Optometric Association (AOA) Optometry’s Meeting taking place June 20-24 in Denver. Notably, Leatrice Eiseman, executive director at the Pantone C
- Foundation Fighting Blindness Launches the Stargardt Disease Natural History Studyhttps://modernod.com/news/foundation-fighting-blindness-launches-the-stargardt-disease-natural-history-study/2480086/More than 60 leading retinal disease clinical researchers from around the world gathered in Baltimore on June 11, 2018 to discuss findings from ProgStar, the Stargardt disease natural history study launched by the Foundation Fighting
- Allergan Announces Former Abbott Executive to Join Board of Directors as Part of “Refreshment Process”https://modernod.com/news/allergan-announces-former-abbott-executive-to-join-board-of-directors-as-part-of-refreshment-process/2480087/Allergan on Thursday said that former Abbott Laboratories executive Thomas Freyman will be joining its board with immediate effect. CEO Brent Saunders remarked “[Freyman] has nearly four decades of industry experience including finance leadership and serving on multiple public boards, makin
- Optovue Announces Expanded FDA Clearance of Epithelial Thickness Mappinghttps://modernod.com/news/optovue-announces-expanded-fda-clearance-of-epithelial-thickness-mapping/2480088/Optovue announced an expanded FDA 510(k) clearance for non-contact, quantitative measurements of the epithelial and stromal layers of the cornea, termed epithelial thickness mapping (ETM). The expanded clearance adds a 9-millimeter ETM scan to the previously available 6-millimeter map, allowing f
- OD-OS Introduces the Navilas expertLibrary Forum for Retina Specialistshttps://modernod.com/news/od-os-introduces-the-navilas-expertlibrary-forum-for-retina-specialists/2480093/OD-OS has introduced a new forum for retina specialists – the Navilas expertLibrary. The Navilas expertLibrary is an exclusive forum where leading retinal physicians share their day-to-day experience with this novel navigated retinal laser technology, according to OD-OS. Interested parties
- GenSight Biologics Reports Positive Additional Data From REVERSE Phase 3 Clinical Trial of GS010 for Treatment of LHONhttps://modernod.com/news/gensight-biologics-reports-positive-additional-data-from-reverse-phase-3-clinical-trial-of-gs010-for-treatment-of-leber-hereditary-optic-neuropathy-lhon/2480100/GenSight Biologics reported additional results from the REVERSE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4)in patients with Leber Hereditary Optic Neuropathy (LHON). The study involved 37 patients with visual loss du
- Group of Takeda Shareholders Call Proposed Shire Purchase “Height of Madness”https://modernod.com/news/group-of-takeda-shareholders-call-proposed-shire-purchase-height-of-madness/2480115/A group of Takeda shareholders have criticized the company’s deal to buy Shire as “the height of madness,” raising concerns over the level of debt that will need to be taken on to fund the purchase, the Financial Times reported. The group hold just over 1 percent of Takeda’